DE602006017586D1 - Anti-myosin-va-sirna und depigmentierung der haut - Google Patents

Anti-myosin-va-sirna und depigmentierung der haut

Info

Publication number
DE602006017586D1
DE602006017586D1 DE602006017586T DE602006017586T DE602006017586D1 DE 602006017586 D1 DE602006017586 D1 DE 602006017586D1 DE 602006017586 T DE602006017586 T DE 602006017586T DE 602006017586 T DE602006017586 T DE 602006017586T DE 602006017586 D1 DE602006017586 D1 DE 602006017586D1
Authority
DE
Germany
Prior art keywords
sirna
sense rna
rna strand
myosine
depigmentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017586T
Other languages
English (en)
Inventor
Anne-Marie Schmitt-Milas
Jo Lambert
Wendy Westbroek
Gele Mireille Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Publication of DE602006017586D1 publication Critical patent/DE602006017586D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602006017586T 2005-12-12 2006-12-12 Anti-myosin-va-sirna und depigmentierung der haut Active DE602006017586D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512553A FR2894582B1 (fr) 2005-12-12 2005-12-12 Sirna anti myosine va et depigmentation de la peau
PCT/EP2006/069618 WO2007068704A1 (fr) 2005-12-12 2006-12-12 Sirna anti myosine va et depigmentation de la peau

Publications (1)

Publication Number Publication Date
DE602006017586D1 true DE602006017586D1 (de) 2010-11-25

Family

ID=36617133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017586T Active DE602006017586D1 (de) 2005-12-12 2006-12-12 Anti-myosin-va-sirna und depigmentierung der haut

Country Status (23)

Country Link
US (1) US7999096B2 (de)
EP (2) EP2264171A1 (de)
JP (1) JP2009518022A (de)
KR (1) KR20080079298A (de)
CN (1) CN101326286A (de)
AT (1) ATE484585T1 (de)
AU (1) AU2006325359A1 (de)
BR (1) BRPI0619738A2 (de)
CA (1) CA2632837A1 (de)
DE (1) DE602006017586D1 (de)
DK (1) DK1963507T3 (de)
ES (1) ES2351996T3 (de)
FR (1) FR2894582B1 (de)
HR (1) HRP20100666T1 (de)
IL (1) IL191728A0 (de)
MA (1) MA30034B1 (de)
NO (1) NO20083089L (de)
PL (1) PL1963507T3 (de)
PT (1) PT1963507E (de)
RU (1) RU2008125041A (de)
TN (1) TNSN08252A1 (de)
WO (1) WO2007068704A1 (de)
ZA (1) ZA200805739B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4981381B2 (ja) * 2006-08-04 2012-07-18 株式会社ナリス化粧品 美白用皮膚外用剤
EP2105145A1 (de) * 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
EP2334282B1 (de) * 2008-09-10 2019-08-07 LvmH Recherche Verfahren zur untersuchung oder modulierung der haut- oder haarpigmentierung, pflanzenextrakte zur verwendung in zusammensetzungen und kosmetisches pflegeverfahren
JP6209309B2 (ja) 2008-09-22 2017-10-04 アールエックスアイ ファーマシューティカルズ コーポレーション サイズが減少した自己送達用ＲＮＡｉ化合物
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
WO2011133876A2 (en) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2013120726A2 (en) * 2012-02-13 2013-08-22 Unilever N.V. A skin lightening composition
CN102925443A (zh) * 2012-11-01 2013-02-13 东北师范大学 靶向沉默MyoⅩ的序列制备及其载体的构建
CN107073294A (zh) * 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
CN105560635A (zh) * 2015-09-17 2016-05-11 张名静 一种治疗黑色棘皮病的中药
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência
JP2022541896A (ja) * 2019-07-18 2022-09-28 オリパス コーポレーション メラノフィリンアンチセンスオリゴヌクレオチド
EP4005602A4 (de) * 2019-07-30 2024-06-12 Shionogi & Co., Ltd Gegen murf1 gerichteter nukleinsäurewirkstoff
WO2024179573A1 (zh) * 2023-03-02 2024-09-06 上海拓界生物医药科技有限公司 靶向抑制素βE的siRNA、siRNA缀合物及其医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772607B1 (fr) 1997-12-19 2000-02-04 Oreal Utilisation de derives amides d'amino phenol comme agents depigmentants
GB9903216D0 (en) 1999-02-13 1999-04-07 Zylepsis Ltd Preservative compounds,compositions and methods of making and using the same
HN2000000033A (es) 1999-03-22 2001-02-02 Pfizer Prod Inc Composicion de resorcinol
ES2238993T3 (es) 1999-03-22 2005-09-16 Pfizer Inc. Derivados de resorcinol.
FR2804960B1 (fr) 2000-02-11 2005-06-24 Lvmh Rech Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
FR2864539B1 (fr) 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
KR20070085113A (ko) * 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법

Also Published As

Publication number Publication date
FR2894582B1 (fr) 2008-02-22
EP1963507B1 (de) 2010-10-13
WO2007068704A1 (fr) 2007-06-21
ES2351996T3 (es) 2011-02-14
IL191728A0 (en) 2011-08-01
PL1963507T3 (pl) 2011-04-29
US7999096B2 (en) 2011-08-16
RU2008125041A (ru) 2010-01-20
ATE484585T1 (de) 2010-10-15
KR20080079298A (ko) 2008-08-29
EP2264171A1 (de) 2010-12-22
CN101326286A (zh) 2008-12-17
NO20083089L (no) 2008-07-10
HRP20100666T1 (hr) 2011-03-31
AU2006325359A1 (en) 2007-06-21
MA30034B1 (fr) 2008-12-01
AU2006325359A2 (en) 2008-07-31
PT1963507E (pt) 2010-11-24
TNSN08252A1 (en) 2009-10-30
CA2632837A1 (fr) 2007-06-21
ZA200805739B (en) 2009-07-29
FR2894582A1 (fr) 2007-06-15
DK1963507T3 (da) 2011-01-03
EP1963507A1 (de) 2008-09-03
US20090239934A1 (en) 2009-09-24
BRPI0619738A2 (pt) 2011-10-11
JP2009518022A (ja) 2009-05-07

Similar Documents

Publication Publication Date Title
ATE484585T1 (de) Anti-myosin-va-sirna und depigmentierung der haut
ATE546526T1 (de) Hybrid-interferenz-rna
WO2010033247A3 (en) Reduced size self-delivering rnai compounds
DK2410054T4 (da) Antisenseforbindelser
AU2008339215A8 (en) Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
GB0507019D0 (en) RNA interference mediated treatment of polyglutamine (polyq) repeat expansion diseases using short interfering nucleic acid (sina)
MX2012002272A (es) Dominios cataliticos de lisil oxidasa y loxl2.
ATE550025T1 (de) Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna)
EP1606304A4 (de) Genexpressionsregulierende nukleotidsequenzen sowie konstrukte und verfahren unter verwendung davon
EP2021507A4 (de) Zusammensetzungen und verfahren zur hemmung der pcsk9-genexpression
WO2006039253A3 (en) Sirna-mediated gene silencing of alpha synuclein
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
WO2006045591A3 (en) Method and constructs for delivering double stranded rna to pest organisms
ATE293688T1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide
Richards et al. RNA bandages for photoregulating in vitro protein synthesis
DE60325494D1 (de) Sirna-gesteuerte genexpressionsunterdrückung in transgenetischen tieren
UA93658C2 (en) Cell surface glycoprotein
BR0115534A (pt) Luciferases isoladas assim como seu emprego
CO2021015542A2 (es) Molécula oligomérica de ácido nucleico y uso de esta en el tratamiento de la porfiria aguda intermitente
AP2851A (en) Use of double stranded RNA hairpin duplexes in gene silencing
ATE529124T1 (de) Verwendung des engrailed homeodomänen-proteins als anxiolytikum
WO2005078090A3 (de) Antisense-oligonukleotide zur behandlung von unerwünschter pigmentierung der haut und der haare
ATE520775T1 (de) Raygraspollen-spezifische promotoren und expressionskonstrukte